The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase Ib study exploring the combination of everolimus and dovitinib in VEGF-refractory clear cell renal cancer.
Amanda Marie Fitzpatrick
No relevant relationships to disclose
Michelle Greenwood
No relevant relationships to disclose
Abigail Foreshew
No relevant relationships to disclose
Jude Nixon
No relevant relationships to disclose
Anju Sahdev
No relevant relationships to disclose
Naveed Sarwar
No relevant relationships to disclose
Louise Lim
No relevant relationships to disclose
Robert J. Jones
Honoraria - Novartis; Pfizer
Simon Chowdhury
Honoraria - Novartis; Pfizer
Simon J. Crabb
Honoraria - Novartis; Pfizer
Thomas Powles
Honoraria - Novartis; Pfizer